Alzheimers Disease Drug Development Program (U01)

The summary for the Alzheimers Disease Drug Development Program (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Alzheimers Disease Drug Development Program (U01): -Purpose. The objective of this solicitation is to stimulate research in the pre-clinical development and testing of novel therapeutic compounds aimed at slowing, halting, or reversing the progressive decline in cognitive function and modifying the behavioral symptoms in Alzheimer's disease (AD); or delaying the onset of or preventing AD, mild cognitive impairment (MCI), or age-related cognitive decline. This initiative is intended to stimulate activities focused on providing sufficient data to submit an Investigational New Drug (IND) application to the Food and Drug Administration to begin human clinical testing of potential new therapies. For this program neither mechanistic/basic studies nor clinical trials will be supported; only applications to develop a therapy will be accepted. -Mechanism of Support. This FOA uses the NIH U01 mechanism -Funds Available and Anticipated Number of Awards. NIA has set aside $2.5 M in total costs in FY2009 for applications submitted in response to this program announcement. However, because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received.
Federal Grant Title: Alzheimers Disease Drug Development Program (U01)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-08-266
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.866
CFDA Descriptions: Aging Research
Current Application Deadline: Jan 07, 2012
Original Application Deadline: Jan 07, 2012
Posted Date: Dec 03, 2008
Creation Date: Dec 03, 2008
Archive Date: Feb 07, 2012
Total Program Funding: $2,500,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations).
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Exploring Molecular Links Between Dietary Interventions and Circadian Rhythm (R01 Clinical...
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical ...
Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
Centers on the Demography and Economics of Alzheimer's Disease and Alzheimer's Related Dem...
Centers on the Demography and Economics of Aging (P30 Clinical Trial Optional)
Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...
Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...
Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
More Grants from the National Institutes of Health
Womens HIV Epidemiology Cohort Studies (R01 Clinical Trial Not Allowed)
Summer Research Education Experience Program (Clinical Trials Not Allowed R25)
Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/...
Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinica...
The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Lab... is not endorsed by, or affiliated with, any government agency. Copyright ©2019